SCHEMBL20766517

SCHEMBL20766517

N#Cc1ccc(OCCF)cc1

nearest known ligand 0.56

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ MMP2 P08253 2/20 0.56
▸ ALDH1A1 P00352 1/20 0.53
▸ MAPT P10636 1/20 0.53
▸ MMP3 P08254 2/20 0.51
▸ MMP1 P03956 1/20 0.51
▸ MMP9 P14780 1/20 0.51
▸ MMP13 P45452 1/20 0.51
▸ HRH3 Q9Y5N1 3/20 0.50
▸ MAOB P27338 1/20 0.50
▸ HDAC1 Q13547 1/20 0.47
▸ HDAC2 Q92769 1/20 0.47
▸ TBXAS1 P24557 1/20 0.47
▸ HRH2 P25021 1/20 0.47
▸ HRH1 P35367 1/20 0.47
▸ APP P05067 5/20 0.47
▸ SIGMAR1 Q99720 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20766346 0.89 HRH3 (0.53) MMP2ALDH1A1MAPTMMP3MMP1
SCHEMBL7986752 0.86 ALDH1A1 (0.66) MMP2ALDH1A1MAPTMMP3MMP1
SCHEMBL14764074 0.85 SLC6A2 (0.54) MMP2ALDH1A1MAPTMMP3MMP1
SCHEMBL7384498 0.84 HRH3 (0.59) MMP2ALDH1A1MAPTMMP3MMP1
SCHEMBL5519875 0.84 HRH3 (0.62) MMP2ALDH1A1MAPTMMP3MMP1
SCHEMBL10457449 0.83 APP (0.59) ALDH1A1APP
SCHEMBL410754 0.83 MMP2 (0.61) MMP2ALDH1A1MAPTMMP3MMP1
SCHEMBL1714571 0.83 TAAR1 (0.56) MMP2ALDH1A1MAPTMMP3MMP1
SCHEMBL9617430 0.82 ALDH1A1 (0.57) MMP2ALDH1A1MAPTMMP3MMP1
SCHEMBL5526919 0.82 HRH3 (0.66) MMP2ALDH1A1MAPTMMP3MMP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025242715-A1 METHOD FOR RAPIDLY PROVIDING PYRIDAZINES FROM TETRAZINES AND CIS-DIENOPHILES TETRAKIT TECHNOLOGIES APS (DK) 2025-11-27 — — WO disclosed
EP-4653425-A1 METHOD FOR RAPIDLY PROVIDING PYRIDAZINES FROM TETRAZINES AND CIS-DIENOPHILES Tetrakit Technologies ApS (DK) 2025-11-26 — — EP disclosed
EP-4635568-A2 COMPOUNDS, SALTS THEREOF AND METHODS FOR TREATMENT OF DISEASES ACADIA Pharmaceuticals Inc. (US) 2025-10-22 — — EP disclosed
EP-3672954-B1 COMPOUNDS, SALTS THEREOF AND THEIR USE FOR THE TREATMENT OF DISEASES ACADIA PHARM INC (US) 2025-08-13 — — EP disclosed
US-20250197385-A1 COMPOUNDS, SALTS THEREOF AND METHODS FOR TREATMENT OF DISEASES ACADIA PHARM INC (US) 2025-06-19 — — US disclosed
US-12139477-B2 Compounds, salts thereof and methods for treatment of diseases ACADIA PHARMACEUTICALS INC. (US) 2024-11-12 — — US disclosed
US-20240182382-A1 ALIPHATIC 18F-RADIOLABELING OF A TETRAZINE PRECURSOR UNIV COPENHAGEN (DK) 2024-06-06 — — US disclosed
CN-117466803-A Compounds, salts thereof and methods for treating diseases 阿卡蒂亚药品公司 2024-01-30 — — CN disclosed
EP-4305009-A2 ALIPHATIC 18F-RADIOLABELING OF A TETRAZINE PRECURSOR University of Copenhagen (DK) 2024-01-17 — — EP disclosed
CN-111132976-B Compounds, salts thereof and methods for treating diseases 阿卡蒂亚药品公司 2023-08-22 — — CN disclosed
WO-2022189304-A2 ALIPHATIC 18F-RADIOLABELING OF A TETRAZINE PRECURSOR UNIVERSITY OF COPENHAGEN (DK) 2022-09-15 — — WO disclosed
EP-4056546-A1 ALIPHATIC 18F-RADIOLABELING OF A TETRAZINE PRECURSOR University of Copenhagen (DK) 2022-09-14 — — EP disclosed
US-11345693-B2 Compounds, salts thereof and methods for treatment of diseases ACADIA PHARMACEUTICALS INC. (US) 2022-05-31 — — US disclosed
US-11345693-B2 Compounds, salts thereof and methods for treatment of diseases ACADIA PHARMACEUTICALS INC. (US) 2022-05-31 — — US disclosed
US-20200270239-A1 COMPOUNDS, SALTS THEREOF AND METHODS FOR TREATMENT OF DISEASES ACADIA PHARMACEUTICALS INC. (US) 2020-08-27 — — US disclosed
US-20200270239-A1 COMPOUNDS, SALTS THEREOF AND METHODS FOR TREATMENT OF DISEASES ACADIA PHARMACEUTICALS INC. (US) 2020-08-27 — — US disclosed
EP-3672954-A1 COMPOUNDS, SALTS THEREOF AND METHODS FOR TREATMENT OF DISEASES Acadia Pharmaceuticals Inc. (US) 2020-07-01 — — EP disclosed
CN-111132976-A Compounds, salts thereof and methods for treating diseases 阿卡蒂亚药品公司 2020-05-08 — — CN disclosed
WO-2019040107-A1 COMPOUNDS, SALTS THEREOF AND METHODS FOR TREATMENT OF DISEASES ACADIA PHARMACEUTICALS INC. (US) 2019-02-28 — — WO disclosed
WO-2019040107-A1 COMPOUNDS, SALTS THEREOF AND METHODS FOR TREATMENT OF DISEASES ACADIA PHARMACEUTICALS INC. (US) 2019-02-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200270239-A1 COMPOUNDS, SALTS THEREOF AND METHODS FOR TREATMENT OF DISEASES SLC10A1, CYP27A1, CYP11B2 MMP2 2254/4885ALDH1A1 240/4885MAPT 1125/4885
US-12139477-B2 Compounds, salts thereof and methods for treatment of diseases SLC10A1, CYP27A1, CYP11B2 MMP2 2254/4885ALDH1A1 240/4885MAPT 1125/4885
US-20240182382-A1 ALIPHATIC 18F-RADIOLABELING OF A TETRAZINE PRECURSOR NBAS, HRAS, NAA15 MMP2 4418/4885ALDH1A1 747/4885MAPT 2572/4885
US-11345693-B2 Compounds, salts thereof and methods for treatment of diseases SLC10A1, CYP27A1, CYP11B2 MMP2 2254/4885ALDH1A1 240/4885MAPT 1125/4885
US-20250197385-A1 COMPOUNDS, SALTS THEREOF AND METHODS FOR TREATMENT OF DISEASES SLC10A1, CYP27A1, CYP11B2 MMP2 2254/4885ALDH1A1 240/4885MAPT 1125/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback